T-Cypher Bio
Michela Marongiu has over a decade of experience in research, specifically in regenerative medicine, liver diseases and cancer. Michela began their postdoctoral research career at the University of Warwick in 2009 and then worked as a postdoctoral research fellow at the Università degli Studi di Cagliari for three years. In 2015, they joined GSK as a Senior Scientist, focusing on vector development, cell and gene therapy. Within GSK, they worked their way up to an Investigator role where they led teams and managed collaborations with external partners. In 2023, they will begin their role as a Principal Scientist at T-Cypher Bio.
Michela Marongiu completed their Bachelor of Science degree in Biological Sciences at the Università degli Studi di Cagliari. Michela then pursued a PhD at the University of Southampton from 2005 to 2009. In 2005, they were awarded a Marie Curie Fellowship at the Katholieke Universiteit Leuven. In 2003, they completed a research internship at the Università degli Studi di Cagliari.
T-Cypher Bio
T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of suchtherapies.T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.